Ciclesonide: A review of its use in the management of asthma

Drugs

Volumn 68, Issue 12, 2008, Pages 1741-1770

  Deeks, Emma D ^a,b   Perry, Caroline M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Asthma; Ciclesonide, general

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CYTOCHROME P450 3A4; EOSINOPHIL CATIONIC PROTEIN; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; HYDROCORTISONE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; ITRACONAZOLE; KETOCONAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NELFINAVIR; OSTEOCALCIN; PLACEBO; PREDNISOLONE; PREDNISONE; RITONAVIR; TRANSFORMING GROWTH FACTOR BETA1;

AIRWAY OBSTRUCTION; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ASTHMA; BACKACHE; BONE DENSITY; BRONCHITIS; BRONCHOSPASM; CATARACT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DRY THROAT; DYSGEUSIA; DYSPNEA; EMBASE; EOSINOPHIL; EXERCISE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; GROWTH RETARDATION; HEADACHE; HOARSENESS; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; METERED DOSE INHALER; NOSE CONGESTION; PEAK EXPIRATORY FLOW; PHARYNGITIS; QUALITY OF LIFE; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; THORAX PAIN; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; WHEEZING;

ADMINISTRATION, INHALATION; ANTI-ALLERGIC AGENTS; ASTHMA; HUMANS; METERED DOSE INHALERS; PREGNENEDIONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49149126491     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868120-00010     Document Type: Review

References (118)

1. Global Initiative for Asthma: global strategy for asthma management and prevention. GINA workshop report: global strategy for asthma management and prevention (updated 2007) [online]. Available from URL: http://www.ginasthma.org [Accessed 2008 Apr 28]
2. British Thoracic Society. British guideline on the management of asthma: a national clinical guideline (revised 2007) [online]. Available from URL: http://www.sign.ac.uk/pdf/sign63.pdf [Accessed 2008 Apr 28]
3. Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimentional and three-dimentional imaging show circlesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006; 19 (2): 117-26
4. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005 Mar; 60 (3): 330-7
5. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320μg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005 Oct; 99 (10): 1275-85
6. Reynolds NA, Scott LJ. Ciclesonide. Drugs 2004; 64 (5): 511-9
7. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999 Jul; 160 (1): 237-43
8. Larsen BB, Nielsen LP, Engelstatter R, et al. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003 Mar; 58 (3): 207-12
9. O'Connor B, Sips P, Engelstätter R, et al. Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 pt 2): A767
10. O'Connor BJ, Kilfeather S, Cheung D, et al. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks [abstract no. 2579]. Eur Respir J 2002 Sep; 20 Suppl. 38: 406s
11. Vermeulen JH, Gyurkovits K, Rauer H, et al. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med 2007 Oct; 101 (10): 2182-91
12. Subbarao P, Duong M, Adelroth E, et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 2006 May; 117 (5): 1008-13
13. Heijink IH, Kauffman HF, Vellenga E, et al. Effect of ciclesonide treatment on allergen-induced changes in T cell regulation in asthma. Int Arch Allergy Immunol 2008; 145 (2): 111-21
14. Weinbrenner A, Hüneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002 May; 87 (5): 2160-3
15. Kanniess F, Richter K, Böhme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001; 14 (2): 141-7
16. Gelfand EW, Georgitis JW, Noonan M, et al. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006 Mar; 148 (3): 377-83
17. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005 Dec; 116 (6): 1206-12
18. Erin EM, Zacharasiewicz AS, Nicholson GC, et al. Rapid anti-inflammatory effect of inhaled ciclesonide in asthma: a randomised, placebo-controlled study. Chest. Epub 2008 Apr 10
19. Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, et al. Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. Respir Med 2006 Sep; 100 (9): 1651-6
20. Cohen J, Douma WR, Ten Hacken NH, et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008 Jun; 31 (6): 1213-20
21. Health Canada. Alvesco® (ciclesonide inhalation aerosol): product monograph [online]. Available from URL: http://cpe0013211b4c6d-cm0014e88ee7a4. cpe.net.cable.rogers.com/dpdonline/displayInfo.do?drugCode=oPskuXySTyo%3D [Accessed 2008 May 8]
22. Sher L, Gillman S, Kundu S, et al. Long-term safety of twice-daily ciclesonide in adults and adolescents with severe, persistent asthma: results from a 52-week study [abstract no. 7]. Ann Allergy Asthma Immunol 2006 Jan 1; 96 (1): 132
23. Kawayama T, O'Byrne PM, Watson RM, et al. Effects of inhaled ciclesonide on circulating T-helper type 1/T-helper type 2 cells in atopic asthmatics after allergen challenge. Clin Exp Allergy 2006 Nov; 36 (11): 1417-24
24. FitzGerald JM, Magnussen H, Engelstätter R. Comparative safety and efficacy of ciclesonide and fluticasone propionate in the management of adult persistent asthma [abstract]. Chest 2007; 132 (4 Suppl.): 508-9s
25. Skoner DP, Maspero J, Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008 Jan; 121 (1): e1-14
26. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005 Apr; 94 (4): 465-72
27. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005 Sep; 128 (3): 1104-14
28. Meltzer EO, Sotomayor JL, Kundu S, et al. Long-term safety profile of once-daily ciclesonide in children with persistent asthma of all severities [abstract no. 34]. Ann Allergy Asthma Immunol 2006 Jan 1; 96 (1): 140-1
29. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005 May; 115 (5): 940-5
30. Berger W, Galant S, Kundu S, et al. Long-term safety profile of once-daily ciclesonide in adults/adolescents with mild-to-moderate persistent asthma [abstract no. 33]. Ann Allergy Asthma Immunol 2006 Jan 1; 96 (1): 140
31. Gauvreau GM, Boulet LP, Postma DS, et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005 Aug; 116 (2): 285-91
32. Lee DKC, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005 Mar 1; 127 (3): 851-60
33. Lee DKC, Haggart K, Currie GP, et al. Effects of hydrofluoro-alkane formulations of ciclesonide 400 μg once daily vs fluticasone 250 μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol 2004 Jul; 58 (1): 26-33
34. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled circlesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18 (5): 328-36
35. Wilson AM, Duong M, Pratt B, et al. Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy 2006 May; 61 (5): 537-42
36. Postma DS, Ind PW, Magnussen H, et al. A double-blind, randomized, controlled study comparing the efficacy and safety of inhaled ciclesonide with oral prednisolone in patients with an asthma exacerbation [abstract]. Proc Am Thorac Soc 2006 Apr; 3 Suppl.: 74
37. von Berg A, Engelstätter R, Minic P, et al. Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma. Pediatr Allergy Immunol 2007 Aug; 18 (5): 391-400
38. Pedersen S, Garcia ML, Manjra A, et al. A comparative study of inhaled ciclesonide 160 μg/day and fluticasone propionate 176 μg/day in children with asthma. Pediatr Pulmonol 2006 Oct; 41 (10): 954-61
39. Bateman E, Karpel J, Casale T, et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006 May; 129 (5): 1176-87
40. Hansel TT, Benezet O, Kafé H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther 2006 Jun; 28 (6): 906-20
41. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2007; 20 (5): 562-70
42. Chapman KR, Patel P, Boulet LP, et al. Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52-week long study [abstract no. 2328]. Eur Respir J Suppl 2002 Sep; 20 Suppl. 38: 373-4
43. Boero S, Sabatini F, Silvestri M, et al. Modulation of human lung fibroblast functions by ciclesonide: evidence for its conversion into the active metabolite desisobutyryl-ciclesonide. Immunol Lett 2007 Sep 15; 112 (1): 39-46
44. Nonaka T, Sugiyama H, Taneda M, et al. Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro [abstract no. P652]. Eur Respir J 2002 Sep; 20 Suppl. 38: 91s
45. Silvestri M, Serpero L, Petecchia L, et al. Cytokine-activated bronchial epithelial cell pro-inflammatory functions are effectively downregulated in vitro by ciclesonide. Pulm Pharmacol Ther 2006; 19 (3): 210-7
46. Clarke DL, Hardaker EH, Birrell MA, et al. Effect of ciclesonide on GM-CSF release and proliferation of human airway smooth muscle cells in culture [abstract no. D88]. Am J Respir Crit Care Med 2004; 169 (7): A871
47. Stoeck M, Hatzelmann A, Belvisi MG, et al. In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cells [abstract no. P679]. Eur Respir J 2001 Sep; 18 Suppl. 33: 95s
48. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Therap 2004 Apr; 309 (1): 249-58
49. Belvisi MG, Bundschuh DS, Stoeck M, et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 2005 Aug; 314 (2): 568-74
50. Hochhaus G, Talton J, Stoeck M. Pulmonary targeting of ciclesonide and its active metabolite as determined in an ex-vivo rat receptor-binding assay [abstract no. P3865]. Eur Respir J 2002; 20: S38
51. Leung SY, Eynott P, Nath P, et al. Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. J Allergy Clin Immunol 2005 May; 115 (5): 989-96
52. Belvisi MG, Hele DJ. Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 2003; 16 (6): 321-5
53. Woodruff PG, Dolganov GM, Ferrando RE, et al. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 2004; 169: 1001-6
54. Bergeron C, Hauber HP, Gotfried M, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005; 116 (5): 983-9
55. Corren J. Evaluation and treatment of asthma: an overview. Am J Manag Care 2005 Nov; 11 (14 Suppl.): S408-15
56. Chung F. Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-γ. Mediators Inflamm 2001 Apr; 10 (2): 51-9
57. Teixeira LK, Fonseca BPF, Barboza BA, et al. The role of interferon-γ on immune and allergic responses. Mem Inst Oswaldo Cruz 2005 Mar; 100 Suppl. 1: 137-44
58. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006 Aug; 100 (8): 1307-17
59. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006 Nov; 28: 1042-50
60. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest 2006 Jul; 130 Suppl. 1: 41-53S
61. Böhmer GM, Drollmann A, Gleiter CH, et al. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl- ciclesonide. Clin Pharmacokinet 2008; 47 (5): 343-9
62. Nave R, Drollmann A, Steinijans VW, et al. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int J Clin Pharmacol Ther 2005 Jul; 43 (6): 264-70
63. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005 May; 61 (3): 203-8
64. 14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 2004; 43 (7): 479-86
65. Nave R, Gunawardena KA, Zech K, et al. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther 2006 Jan 1; 44 (1): 1-7
66. Nave R, Bethke TD, Seiberling M, et al. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects [abstract no. P749]. Eur Respir J 2002 Sep; 20 Suppl. 38: 110s
67. 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006 Mar 1; 100 (3): 375-84
68. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005 Feb 1; 45 (2): 146-52
69. Drollmann A, Nave R, Steinijans VW, et al. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus™ spacer for inhalation. Clin Pharmacokinet 2006; 45 (7): 729-36
70. Drollmann A, Watz H, Nave R, et al. In vivo metabolism of ciclesonide in the human lung [abstract]. Proc Am Thorac Soc 2006 Apr 1; 3 Suppl.: 75
71. Krishnaswami S, Pfister M, Rohatagi S. Population pharmacokinetics/ pharmacodynamic analysis of the active metabolite of ciclesonide [abstract no. W4350]. AAPS Journal 2004; 6 (4 Suppl.)
72. Nycomed UK Ltd. Alvesco® 160 inhaler: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/ assets/c/html/displayDocPrinter-Friendly.asp?documentid=15768 [Accessed 2008 May 8]
73. Nycomed UK Ltd. Alvesco® 80 inhaler: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/ assets/c/html/displayDocPrinter-Friendly.asp?documentid=19707 [Accessed 2008 May 8]
74. Lexmüller K, Gullstrand H, Axelsson BO, et al. Differences in endogenous esterification and retention in the rat trachea between budesonide and ciclesonide active metabolite. Drug Metab Dispos 2007 Oct; 35 (10): 1788-96
75. Sato H, Nave R, Nonaka T, et al. In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharm Drug Dispos 2006 Nov 21; 28 (1): 43-50
76. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007 May 15; 73 (10): 1657-64
77. Peet CF, Enos T, Nave R, et al. Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet 2005 Oct-Dec; 30 (4): 275-86
78. Nonaka T, Nave R, McCracken N, et al. Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549). BMC Pharmacol 2007 Sep 27; 7: 12
79. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005 May-Jun; 12 (3): 201-9
80. Chu V, Zeng Z, Pan J, et al. In vitro assessment of cytochrome P450 metabolic drug-drug interaction potential of ciclesonide [abstract no. 552]. Drug Metab Rev 2004; 36 Suppl. 1: 276
81. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006 May; 27 (4): 197-207
82. Nave R, Fisher R, McCracken N. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices. Respir Res 2007 Sep 20; 8 (1): 65
83. Nave R, Meyer W, Fuhst R, et al. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005; 18 (6): 390-6
84. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2006; 19 (6): 404-12
85. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of once-daily inhaled ciclesonide in adults with mild to moderate asthma: a double-blind, placebo-controlled study. Respirology 2007 Jul; 12 (4): 566-72
86. Knox A, Langan J, Martinot JB, et al. Comparison of a stepdown dose of once-daily ciclesonide with a continued dose of twice-daily fluticasone propionate in maintaining control of asthma. Curr Med Res Opin 2007 Aug 21; 23 (10): 2387-94
87. Weinstein S, Friedman B, Kundu S, et al. Ciclesonide is effective and well tolerated in adult/adolescents with severe, persistent asthma [abstract]. Proc Am Thorac Soc 2005 Jan 1; 2 Suppl.: A355
88. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of inhaled ciclesonide compared with chlorofluorocarbon beclomethasone dipropionate in adults with moderate to severe persistent asthma. Respirology 2007 Jul; 12 (4): 573-80
89. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160μg QD and budesonide 200μg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 2005 Nov; 27 (11): 1752-63
90. Boulet LP, Drollmann A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006 May; 100 (5): 785-94
91. Boulet L-P, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007 Aug; 101 (8): 1677-86
92. Magnussen H, Hofman J, Staneta P, et al. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. J Asthma 2007 Sep; 44 (7): 563-63
93. Bateman ED, Linnhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008; 21 (2): 264-75
94. Hiremath L, Kumar TM, Singh V, et al. Comparison of once- daily ciclesonide 160μg versus twice-daily fluticasone propionate 88 μg in children with moderate to severe asthma [abstract no. P4089]. Eur Respir J Suppl 2006 Sep; 28 Suppl. 50: 711
95. Pedersen S, Cruz AA, Fiterman J, et al. Comparison of ciclesonide once daily (80 μg/day, 160 μg/day) and fluticasone propionate twice daily (176 μg/day) in the treatment of children with persistent asthma [abstract no. E2700]. Eur Respir J Suppl 2007 Sep; 30 Suppl. 51: 458
96. Bateman ED, Cheung D, Lapa e Silva J, et al. Randomized comparison of ciclesonide 160 and 640 μg/day in severe asthma. Pulm Pharmacol Ther. Epub 2007 Nov 22
97. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001 Jun; 17 (6): 1083-8
98. Chhabra SK, Kaushik S. Validation of the Asthma Quality of Life Questionnaire (AQLQ-UK English version) in Indian asthmatic subjects. Indian J Chest Dis Allied Sci 2005; 47: 167-73
99. Pljaskic-Kamenov SS, Djordjevic DV, Radic SS, et al. Asthma quality of life is a marker of disease severity and treatment evaluation in school children. Facta Universitatis: Medicine and Biology 2002; 9 (2): 175-80
100. Bernstein D, Nathan R, Ledford D, et al. Ciclesonide, a new inhaled corticosteroid, significantly improves asthma-related quality of life in patients with severe, persistent asthma [abstract no. 836]. J Allergy Clin Immunol 2005 Feb; 115 Suppl. 2: 210
101. Nayak A, Charous BL, Finn A, et al. A novel inhaled corticosteroid ciclesonide significantly improves quality of life in patients with mild-to-moderate asthma [abstract no. 837]. J Allergy Clin Immunol 2005 Feb; 115 Suppl. 2: 210
102. Alvesco 80/160: Swiss prescribing information. Dübendorf: Nycomed Pharma, 2008
103. Engelstätter R, Escher A, Häfner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide [abstract no. P1738]. Eur Respir J Suppl 2005 Sep; 26 Suppl. 49: 252
104. Banerji D, Szwarcberg J, Fish J, et al. Ciclesonide and placebo have similar incidence of oropharyngeal adverse events in adolescent/adult and pediatric asthma patients: results from pooled analyses [abstract]. Allergy Asthma Proc 2004 May-Jun; 25 (3): 206
105. Alvesco 80/160: Swiss prescribing information. Dübendorf: Nycomed Pharma, 2008
106. National Heart, Lung and Blood Institute. Expert panel report: guidelines for the diagnosis and management of asthma - update on selected topics 2002. J Allergy Clin Immunol 2002 Nov; 110 (5): S141-219
107. National Heart Lung and Blood Institute. Guidelines for the diagnosis and management of asthma: National Asthma Education and Prevention Programme expert panel report 3 [online]. Available from URL: http://www.nhlbi.nih.gov/ guidelines/asthma/asthsumm.htm [Accessed 2008 Jun 12]
108. Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 2007; 20 (1): 23-5
109. Rachelefsky GS, Li H, Liao N, et al. Inhaled corticosteroids and the risk of oropharyngeal adverse events: results from a meta-analysis [abstract no. 358]. J Allergy Clin Immunol 2006; 117 (2 Suppl.): S92
110. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114: 1288-93
111. Baena-Cagnani C, Blaiss M, Canonica W, et al. Global Asthma Physician and Patient (GAPP) Survey: patient eduction and patient-physician communications - UK findings [abstract no. P15]. Thorax 2005; 60 Suppl. 2: ii57
112. Crivera C, Szwarcberg J, Kaliner M, et al. Reasons for nonadherence to inhaled corticosteroid (ICS) therapy in persistent asthma [abstract]. Proc Am Thorac Soc 2005; 2 Suppl.: A587
113. Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 2004; 3 (1): 35-44
114. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44 (1): 37-47
115. Kraft M. The distal airways: are they important in asthma? Eur Respir J 1999; 14: 1403-17
116. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006; 100: 1297-306
117. Mikhak Z. Dose-response studies of fluticasone propionate and budesonide: classification based on asthma severity. Allergy Asthma Proc 2006 Sep-Oct 31; 27 (5): 402-11
118. Braman SS. The global burden of asthma. Chest 2006 Jul; 130 (1 Suppl.): 4-12S